Literature DB >> 1730155

Monocyte-derived macrophage function in HIV-infected subjects: in vitro modulation by rIFN-gamma and rGM-CSF.

F Capsoni1, F Minonzio, A M Ongari, G P Rizzardi, A Lazzarin, C Zanussi.   

Abstract

We investigated monocyte-derived macrophage function in 25 HIV-positive patients, 19 in the CDC class III and 6 class IV; 17 were intravenous drug abusers (IVDA) and 8 were homosexual men. Macrophages from HIV-positive patients behaved normally in assays of superoxide anion (O2-) production and candidacidal activity. After 3 days' treatment with 200 U/ml recombinant interferon-gamma (rIFN-gamma) or 250 U/ml recombinant granulocyte/macrophage-colony stimulating factor (rGM-CSF), both control and HIV-positive patients' phagocytes expressed the activated state, as indicated by the increased O2- production in response to phagocytable or soluble stimuli; however, these cytokines did not enhance candidacidal activity. Compared to appropriate HIV-negative controls (18 healthy heterosexuals, 4 homosexuals and 4 IVDA), macrophages from 19 of the 25 HIV-positive patients presented a significant defect in their Fc receptor (FcR)-dependent phagocytosis, independently from the CDC stage, AZT therapy, or life style. Treatment of macrophages with rIFN-gamma impaired their capacity to ingest IgG-coated erythrocytes, both in controls and HIV-positive subjects. Treatment of phagocytes with rGM-CSF significantly increased their FcR-dependent phagocytosis in controls, whereas in HIV-positive patients and in HIV-negative homosexuals and IVDA only an upward tendency was observed. Although the mechanism of the impaired FcR-dependent phagocytosis in HIV-positive patients remain to be clarified, our results suggest that this functional defect may be secondary to phagocyte priming by circulating IFN-gamma in vivo. This macrophage alteration may be implicated in the immunodeficiency of HIV-positive patients. However, considering the potential role of FcRs in HIV infection enhancement, the defective FcR function might even be a protective mechanism against FcR-mediated HIV dissemination. In the light of these findings, the immunotherapeutic potential of IFN-gamma and GM-CSF in HIV infection merits further investigation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730155     DOI: 10.1016/0090-1229(92)90070-5

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  5 in total

1.  Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome.

Authors:  Pawel Ciborowski; Irena Kadiu; Wojciech Rozek; Lynette Smith; Kristen Bernhardt; Melissa Fladseth; Mary Ricardo-Dukelow; Howard E Gendelman
Journal:  Virology       Date:  2007-02-22       Impact factor: 3.616

2.  Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.

Authors:  J Trial; H H Birdsall; J A Hallum; M L Crane; M C Rodriguez-Barradas; A L de Jong; B Krishnan; C E Lacke; C G Figdor; R D Rossen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

3.  HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression.

Authors:  S J Kent; G Stent; S Sonza; S D Hunter; S M Crowe
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

4.  Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients.

Authors:  W A Nockher; L Bergmann; J E Scherberich
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

5.  HIV-1 inhibits phagocytosis and inflammatory cytokine responses of human monocyte-derived macrophages to P. falciparum infected erythrocytes.

Authors:  Louise E Ludlow; Jingling Zhou; Emma Tippett; Wan-Jung Cheng; Wina Hasang; Stephen J Rogerson; Anthony Jaworowski
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.